Buy Darzalex (daratumumab)
Who is Darzalex (daratumumab) for?
Darzalex (daratumumab) is indicated for patients with:-
newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.
-
multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.
-
multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (third-line treatment). For this indication, it is used in combination with pomalidomide and dexamethasone.
-
multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.
Buy Ibrance (palbociclib)
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (an hormonal therapy) as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it has to go through four phases. The first phase is a growth phase (G1-phase), the second a synthesis phase (S-phase), the third another growth phase (G2-phase) and the last phase, where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Palbociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6)—two proteins that are involved in entering the S-phase[1].
Buy Kadcyla (Trastuzumab Emtansine)
Buy Keytruda (pembrolizumab)
Buy Opdivo (Nivolumab)
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with:- metastatic melanoma as a single agent or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
- advanced renal cell carcinoma who have received prior anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
- locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
- microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
- hepatocellular carcinoma in patients who have been previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
Buy Perjeta (Pertuzumab)
What is Perjeta (pertuzumab) for?
Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Buy Tecentriq (Atezolizumab)
